Show simple item record

dc.contributor.authorEdeline, J.
dc.contributor.authorLamarca, Angela
dc.contributor.authorMcNamara, Mairead G
dc.contributor.authorJacobs, Timothy
dc.contributor.authorHubner, Richard A
dc.contributor.authorPalmer, D.
dc.contributor.authorGroot Koerkamp, B.
dc.contributor.authorJohnson, P.
dc.contributor.authorGuiu, B
dc.contributor.authorValle, Juan W
dc.date.accessioned2021-08-17T12:22:43Z
dc.date.available2021-08-17T12:22:43Z
dc.date.issued2021en
dc.identifier.citationEdeline J, Lamarca A, McNamara MG, Jacobs T, Hubner RA, Palmer D, et al. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. Cancer Treatment Reviews. 2021 Sep;99:102258.en
dc.identifier.pmid34252720en
dc.identifier.doi10.1016/j.ctrv.2021.102258en
dc.identifier.urihttp://hdl.handle.net/10541/624441
dc.description.abstractBackground: Locoregional treatments (LRT) including radioembolisation (SIRT), transarterial chemo-embolisation (TACE), hepatic arterial infusion (HAI) of chemotherapy, external beam radiotherapy (EBRT) and ablation have been studied for the management of intrahepatic cholangiocarcinoma (iCC). The aim of this systematic review was to provide outcome benchmarks for clinical trial design. Methods: Identification of studies reporting outcomes of patients treated with LRT for iCC was performed using PubMed and Embase. Pooled weighted means were calculated for progression-free survival (PFS) and overall survival (OS); meta-analysis of proportions was used for estimation of pooled response rate. Results: 6325 entries were reviewed; 93 studies were eligible, representing 101 cohorts and 3990 patients: 15 cohorts (645 patients) for ablation, 18 cohorts (541 patients) for EBRT, 27 cohorts (1232 patients) for SIRT, 22 cohorts (1145 patients) for TACE, 16 cohorts (331 patients) for HAI and 3 cohorts (96 patients) not pooled. 74% of the studies were retrospective, 99% non-randomised. The pooled mean weighted OS was 30.2 months (95% confidence interval (CI): 21.8-38.6) for ablation, 18.9 (14.2-23.5) for EBRT, 14.1 (12.1-16.0) for SIRT, 15.9 (12.9-19.0) for TACE and 21.3 (15.4-27.1) for HAI. The pooled complete response rate was 93.9% for ablation. When analysed together, SIRT, TACE and HAI had a pooled mean weighted OS of 15.7 months, and 25.2 months for patients treated in first-line with concomitant systemic chemotherapy. Conclusions: Available literature on LRT for iCC was heterogeneous and of insufficient quality to make strong recommendations. Ablation achieved satisfactory outcomes, and may be recommended when surgery is not feasible.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.ctrv.2021.102258en
dc.titleLocoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysisen
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Centre Eugène Marquis, Rennes, France.en
dc.identifier.journalCancer Treatment Reviewsen
dc.description.noteen]
refterms.dateFOA2021-08-18T09:21:31Z


Files in this item

Thumbnail
Name:
34252720.pdf
Size:
812.2Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record